...
首页> 外文期刊>American Journal of Perinatology >Warfarin-associated fetal intracranial hemorrhage in woman with mitral valve replacements: a case report.
【24h】

Warfarin-associated fetal intracranial hemorrhage in woman with mitral valve replacements: a case report.

机译:华法林相关的二尖瓣置换术妇女的胎儿颅内出血:病例报告。

获取原文
获取原文并翻译 | 示例

摘要

Warfarin-associated fetal hemorrhage is a fatal event. We report the case of a 39-year-old woman who had been taking warfarin for 23 years since undergoing mitral valve replacement. Thereafter, when she was found to be pregnant, the medication was switched to heparin from 6 to 21 weeks of gestation. Following this, she was prescribed oral warfarin again (3.5 mg per day), with a strict control of prothrombin time/international normalized ratio (PT/INR). At 23 weeks of gestation, fetal intracranial hemorrhage occurred because of maternal exposure to warfarin. Maternal PT/INR does not correlate well with the activity of warfarin in the fetus and currently, there is no direct way to prevent fetal intracranial hemorrhage. Hence, further research on the optimal coagulation therapy in pregnant women with valve replacement should be encouraged.
机译:华法林相关的胎儿出血是致命事件。我们报告了一名自二尖瓣置换术后服用华法林23年的39岁妇女的病例。此后,当发现她怀孕时,从妊娠6到21周将药物改为肝素。在此之后,她再次被处方口服华法林(每天3.5 mg),并严格控制凝血酶原时间/国际标准化比率(PT / INR)。妊娠23周时,由于母体接触华法令而导致胎儿颅内出血。孕妇的PT / INR与华法林在胎儿体内的活性并没有很好的相关性,目前,尚无直接的方法可以预防胎儿颅内出血。因此,应鼓励对有瓣膜置换术的孕妇进行最佳凝血治疗的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号